Cyclacel Pharmaceuticals (CYCC) CEO pay: $847,436 actually paid in FY2025
$CYCC · Cyclacel Pharmaceuticals, Inc.Data through FY2025 — latest proxy filed 2026-04-27, checked for new filings 2026-08-21. Every number links to its source.
0.2× the tracked-company median CEO pay ($3.9M).
Pay vs. Performance (Compensation Actually Paid)
What the CEO was actually paid, by fiscal year
A negative figure is not pay returned. Compensation Actually Paid re-values unvested equity every year, so when a stock falls, the write-down on awards granted earlier can exceed everything granted that year. How CAP is calculated
What $100 invested was worth, company vs peer group
Pay by CEO — and how the company did on their watch
Item 402(v) reports CEO pay per person, so each row below is one CEO's own disclosed pay next to the company's performance over the same years. A CEO is counted as serving a year when the filing reports a non-zero amount for them. CYCC discloses 3 CEOs across this window.
| CEO | Years | Pay actually earned, total | $100 over their tenure | Net income |
|---|---|---|---|---|
| Datuk Dr Doris Wong Sing Ee | FY2025 | $50,536 | $0.06 | $3.0M |
| David Lazar | FY2025 | $66,250 | $0.06 | $3.0M |
| Spiro Rombotis | FY2023–FY2025 | $1.5M | $4.58 → $0.06 | $22.6M → $3.0M |
FY2022 — -$77,717 of pay actually earned — is reported without an individual tag, in a filing that names 3 CEOs. The amounts are in the table below. We read the filing's machine-readable Item 402(v) tags, and these years carry no IndividualAxis member, so they are not added to any row above — the proxy may still say whose they are in its footnote prose, which we do not parse.
Pay-vs-performance disclosure began with FY2022 filings, so this window reaches back 4 fiscal years — there is no earlier CEO pay in the SEC's structured data.
Pay-vs-Performance table
| FY | CEO pay on paper | CEO pay actually earned | Other top execs (avg) | Value of $100 invested since FY2022 | Same, peer group since FY2022 | Net income |
|---|---|---|---|---|---|---|
| 2025 | $847,436 | $847,436 | $504,968 | $0.06 | — | $3.0M |
| 2024 | $585,000 | $547,706 | $342,889 | $0.64 | — | $11.2M |
| 2023 | $661,049 | $65,807 | $172,676 | $4.58 | — | $22.6M |
| 2022 | $763,551 | -$77,717 | -$36,347 | $17.15 | — | $21.2M |
A negative figure is not pay returned. Compensation Actually Paid re-values unvested equity every year, so when a stock falls, the write-down on awards granted earlier can exceed everything granted that year. How CAP is calculated
Frequently asked
How much did the CYCC CEO make in 2025?
$847,436 in Compensation Actually Paid (CAP) as Cyclacel Pharmaceuticals, Inc.'s CEO — 3 people are tagged as PEO for this year (Datuk Dr Doris Wong Sing Ee, David Lazar, Spiro Rombotis); this is the largest single figure, see the per-CEO table below, updated 2026-04-27.
What is pay vs. performance (PvP)?
An SEC disclosure (Item 402(v), required since FY2022) linking named-executive pay to company total shareholder return (TSR) over up to 5 years.
What is Compensation Actually Paid (CAP)?
CAP starts from the Summary Compensation Table total and adjusts equity awards to fair value as of each year-end/vesting date, rather than grant-date value — see the glossary entry for the full walk-through.
Also on CYCC: SEC & DOJ enforcement actions · CEO track-record ranking · Glossary